Mounjaro
Mounjaro is the type 2 diabetes-labeled version of Zepbound (tirzepatide). Compare costs, prescribing access, and off-label weight-loss use.
- Manufacturer
- Eli Lilly
- Drug class
- Dual GIP/GLP-1 receptor agonist
- Dose range
- 2.5 mg → 15 mg weekly
- Average monthly cost
- $1,069 without insurance · $25 with most diabetes plans
- Insurance covered
- Often, with prior authorization
Overview
Mounjaro is tirzepatide labeled for type 2 diabetes — the same molecule as Zepbound at the same doses, but priced through diabetes channels. Like Ozempic versus Wegovy, off-label prescribing for weight loss is common but rarely covered by insurance for weight-loss indication.
How it works
Dual GIP/GLP-1 agonist with the same mechanism and potency as Zepbound. Significant weight loss is a well-documented secondary outcome.
Side effects
- Nausea, diarrhea, decreased appetite
- Injection-site reactions
- Rare: pancreatitis, gallbladder disease, hypoglycemia in combination with insulin
Who should consider Mounjaro
Adults with type 2 diabetes seeking both glycemic control and weight reduction. Off-label weight-loss use is possible but typically requires cash pay.
Telehealth programs that prescribe Mounjaro
Editorial only — not medical advice. Drug pricing and availability change frequently; verify with the prescribing program before relying on any figure on this page.